title: SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.
abstract: OBJECTIVE
  Cixutumumab, formerly IMC-A12, is a recombinant human monoclonal immunoglobulin G1 antibody that targets insulin-like growth factor I receptor (IGF-IR). Cixutumumab was synergistic with castration in a hormone-sensitive prostate cancer xenograft model.
  
  
  METHODS
  Patients with new metastatic prostate cancer were randomly assigned within 30 days of initiating androgen deprivation (AD) to cixutumumab added to a luteinizing hormone-releasing hormone agonist with bicalutamide versus AD alone. With 180 patients and one-sided alpha of 0.10, there would be 90% power to detect an absolute 20% difference in undetectable prostate-specific antigen (PSA; ≤ 0.2 ng/mL) rate at 28 weeks (relative risk, 1.44); this end point was previously strongly correlated with survival. Secondary end points included the proportion of patients with PSA > 4.0 ng/mL, safety and tolerability, circulating tumor cell (CTC) levels, and seven plasma IGF-IR biomarkers. Fisher's exact test was used for the primary end point, and extended Mantel-Haenszel χ(2) test was used for three PSA response categories.
  
  
  RESULTS
  The trial accrued 210 eligible patients (105 randomly assigned to each arm). Patient characteristics were similar in both arms. Undetectable PSA rate was 42 (40.0%) of 105 for cixutumumab plus AD and 34 (32.3%) of 105 for AD alone (relative risk, 1.24; one-sided P = .16). Lower baseline CTCs (0 v 1 to 4 v ≥ 5/7.5 mL whole blood) were associated with higher rate of PSA response (three categories; P = .036) in 39 evaluable patients. IGF-IR biomarkers were not correlated with PSA outcome, and cixutumumab did not significantly change these biomarker levels.
  
  
  CONCLUSIONS
  Cixutumumab plus AD did not significantly increase the undetectable PSA rate in men with new metastatic hormone-sensitive prostate cancer. CTCs at baseline may carry prognostic value.
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX. evanyu@u.washington.edu.
authors.forename: Evan Y
authors.initials: EY
authors.lastname: Yu
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.
authors.forename: Hongli
authors.initials: H
authors.lastname: Li
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.
authors.forename: Celestia S
authors.initials: CS
authors.lastname: Higano
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.
authors.forename: Neeraj
authors.initials: N
authors.lastname: Agarwal
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.
authors.forename: Sumanta K
authors.initials: SK
authors.lastname: Pal
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.
authors.forename: Ajjai
authors.initials: A
authors.lastname: Alva
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.
authors.forename: Elisabeth I
authors.initials: EI
authors.lastname: Heath
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.
authors.forename: Elaine T
authors.initials: ET
authors.lastname: Lam
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.
authors.forename: Shilpa
authors.initials: S
authors.lastname: Gupta
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.
authors.forename: Michael B
authors.initials: MB
authors.lastname: Lilly
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Inoue
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.
authors.forename: Kim N
authors.initials: KN
authors.lastname: Chi
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Vogelzang
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.
authors.forename: David I
authors.initials: DI
authors.lastname: Quinn
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.
authors.forename: Heather H
authors.initials: HH
authors.lastname: Cheng
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Plymate
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.
authors.forename: Maha
authors.initials: M
authors.lastname: Hussain
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Tangen
authors.affiliation: Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.
authors.forename: Ian M
authors.initials: IM
authors.lastname: Thompson
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000813:Anilides / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D004334:Drug Administration Schedule; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009360:Neoplastic Cells, Circulating; D009570:Nitriles / Q000008:administration & dosage; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D017526:Receptor, IGF Type 1 / Q000097:blood*; D014105:Tosyl Compounds / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D000813:Anilides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D009570:Nitriles; D014105:Tosyl Compounds; C557414:cixutumumab; D007987:Gonadotropin-Releasing Hormone; C053541:bicalutamide; D017526:Receptor, IGF Type 1; D017430:Prostate-Specific Antigen
references.citation: J Clin Endocrinol Metab. 2013 May;98(5):E820-8
references.pmid: 23533230
references.citation: Clin Cancer Res. 2008 Oct 1;14(19):6302-9
references.pmid: 18829513
references.citation: PLoS One. 2013;8(7):e69239
references.pmid: 23935962
references.citation: Clin Cancer Res. 2014 Apr 1;20(7):1925-34
references.pmid: 24536060
references.citation: Cancer Metastasis Rev. 2014 Sep;33(2-3):607-17
references.pmid: 24414227
references.citation: Prostate. 2003 Jun 1;55(4):239-46
references.pmid: 12712403
references.citation: Clin Cancer Res. 2005 Apr 15;11(8):3065-74
references.pmid: 15837762
references.citation: Endocr Rev. 2007 Feb;28(1):20-47
references.pmid: 16931767
references.citation: Clin Cancer Res. 2007 Nov 1;13(21):6429-39
references.pmid: 17975155
references.citation: Urology. 2012 Dec;80(6):1328-32
references.pmid: 23063057
references.citation: Urol Clin North Am. 2012 Nov;39(4):561-71
references.pmid: 23084531
references.citation: Clin Cancer Res. 2012 Jun 15;18(12):3407-13
references.pmid: 22553344
references.citation: Clin Genitourin Cancer. 2011 Sep;9(1):31-8
references.pmid: 21705286
references.citation: Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6153-60
references.pmid: 17062692
references.citation: J Cell Biochem. 2006 Oct 1;99(2):392-401
references.pmid: 16639715
references.citation: J Clin Oncol. 2006 Aug 20;24(24):3984-90
references.pmid: 16921051